Following an exhaustive selection process, Unibaio successfully secured a spot in the coveted cohort of IndieBio NY for the year 2023—a respected and well-known acceleration program tailored for biotech startups.

Matias Figliozzi, CEO of Unibaio, expressed “it is truly an honor for us to become part of IndieBio, renowned for having one of the most distinguished acceleration programs globally for biotechnology and life sciences startups. This not only provides us with crucial access to capital but also invaluable networks essential for our development.”

In Figliozzi’s own words, “our inclusion in their program serves as a substantial endorsement of the vision we are cultivating, particularly for potential investors and Venture Capital entities, who may not typically consider Latin America as a prime destination for investment opportunities.”

Acknowledging the responsibility that comes with this recognition, Figliozzi emphasized that “our participation in the IndieBio NY program is, therefore, a responsibility we take seriously. We understand that we are paving the way for numerous Latin American biotech startups to follow in our footsteps. Our aim is to leave a lasting impact by positioning the scientific endeavors of our countries favorably and inspiring an increasing number of investors to place their stakes on Latin talent.”

The founder of Unibaio states that he is optimistic that their acceptance into IndieBio NY will serve as a pivotal moment in the company’s trajectory. They anticipate making optimal use of the resources and knowledge that IndieBio imparts to the startups under its wing.

“Being part of IndieBio offers us a unique opportunity to dive into a collaborative ecosystem, fueling our growth in the northern hemisphere while propelling our innovations to unprecedented heights,” concluded the CEO, expressing the transformative potential that lies ahead for Unibaio within the IndieBio community.